The difference in serum proteomes in schizophrenia and bipolar disorder

Area of Science:

• Biochemistry
• Neuroscience
• Psychiatry

Background:

• Schizophrenia and bipolar disorder (BD) are complex endogenous psychotic disorders.
• Understanding their underlying biological mechanisms requires identifying disease-specific biomarkers.
• Serum proteome analysis offers a promising avenue for biomarker discovery.

Purpose of the Study:

• To identify significant differences in serum proteomic profiles between schizophrenia and bipolar disorder (BD).
• To uncover potential protein biomarkers associated with each disorder.
• To explore novel biological pathways implicated in these conditions.

Main Methods:

• Quantitative mass-spectrometry-based proteomic analysis of human blood serum.
• Depletion of six major blood proteins to enhance detection of low-abundance proteins.
• Enzyme-linked immunosorbent assay (ELISA) for targeted protein validation (ANKRD12, Cadherin 5).

Main Results:

• Discovery of 27 specific proteins for schizophrenia and 18 for BD.
• Schizophrenia-associated proteins linked to immune response, cell communication, and metabolism.
• BD-associated proteins linked to immune response, cell communication, and neurodevelopment.
• Elevated serum levels of ankyrin repeat domain-containing protein 12 (ANKRD12) in schizophrenia and BD.
• Differential Cadherin 5 concentrations observed between schizophrenia subtypes (positive vs. negative symptoms).

Conclusions:

• The identified protein signatures offer potential biomarkers for differentiating schizophrenia and BD.
• These findings contribute to understanding the distinct pathophysiological pathways of these disorders.
• The results may facilitate the discovery of new therapeutic targets for endogenous psychotic disorders.